Literature DB >> 25645355

Aberrant B-cell homeostasis in chronic GVHD.

Stefanie Sarantopoulos1, Jerome Ritz2.   

Abstract

Recent studies have compelled further interest in the potential pathological role of B cells in chronic graft-versus-host disease (cGVHD). In patients with cGVHD, B cells are activated and primed for survival via B-cell activating factor and B-cell receptor-associated pathways. Understanding the signaling pathways that drive immune pathology in cGVHD will facilitate the development of new strategies to selectively target aberrantly activated B cells and restore normal B-cell homeostasis after allogeneic stem cell transplantation.
© 2015 by The American Society of Hematology.

Entities:  

Mesh：

Year:  2015        PMID： 25645355      PMCID： PMC4357579          DOI： 10.1182/blood-2014-12-567834

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  67 in total

1.  Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies.

Authors:  P Kier; E Penner; S Bakos; P Kalhs; K Lechner; B Volc-Platzer; J Wesierska-Gadek; G Sauermann; H Gadner; W Emminger-Schmidmeier
Journal:  Bone Marrow Transplant       Date:  1990-08       Impact factor: 5.483

2.  Cutting edge: Hierarchy of maturity of murine memory B cell subsets.

Authors:  Mary M Tomayko; Natalie C Steinel; Shannon M Anderson; Mark J Shlomchik
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

3.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

4.  Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones.

Authors:  Isabelle Isnardi; Yen-Shing Ng; Laurence Menard; Greta Meyers; David Saadoun; Iva Srdanovic; Jonathan Samuels; Jessica Berman; Jane H Buckner; Charlotte Cunningham-Rundles; Eric Meffre
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

5.  Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

Authors:  Yohei Iwata; Takashi Matsushita; Mayuka Horikawa; David J Dilillo; Koichi Yanaba; Guglielmo M Venturi; Paul M Szabolcs; Steven H Bernstein; Cynthia M Magro; Armistead D Williams; Russell P Hall; E William St Clair; Thomas F Tedder
Journal:  Blood       Date:  2010-10-20       Impact factor: 22.113

6.  Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease.

Authors:  Dongchang Zhao; James S Young; Yu-Hong Chen; Elizabeth Shen; Tangsheng Yi; Ivan Todorov; Peiguo G Chu; Stephen J Forman; Defu Zeng
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

7.  Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia.

Authors:  Zoya Kuzmina; Hildegard T Greinix; Roman Weigl; Ulrike Körmöczi; Arno Rottal; Sophie Frantal; Sandra Eder; Winfried F Pickl
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

8.  Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells.

Authors:  Santi Suryani; David A Fulcher; Brigitte Santner-Nanan; Ralph Nanan; Melanie Wong; Peter J Shaw; John Gibson; Andrew Williams; Stuart G Tangye
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

9.  Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment.

Authors:  R P Witherspoon; R Storb; H D Ochs; N Fluornoy; K J Kopecky; K M Sullivan; J H Deeg; R Sosa; D R Noel; K Atkinson; E D Thomas
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

10.  Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.

Authors:  Emmanuel Zorn; David B Miklos; Blair H Floyd; Alex Mattes-Ritz; Luxuan Guo; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307
View more
  50 in total

1.  Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.

Authors:  Z DeFilipp; M Purcell; W A C Harris; D J Chandra; C Gleason; J Wrammert; S Sarantopoulos; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

2.  Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Authors:  C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

Review 3.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 4.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 5.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

6.  PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Authors:  Takeru Asano; Yusuke Meguri; Takanori Yoshioka; Yuriko Kishi; Miki Iwamoto; Makoto Nakamura; Yasuhisa Sando; Hideo Yagita; John Koreth; Haesook T Kim; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Yoshinobu Maeda; Mitsune Tanimoto; Jerome Ritz; Ken-Ichi Matsuoka
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

7.  Antibodies are back for thymic attack in cGVHD.

Authors:  Stefanie Sarantopoulos
Journal:  Blood       Date:  2016-05-05       Impact factor: 22.113

8.  Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity.

Authors:  Xiaohui Kong; Deye Zeng; Xiwei Wu; Bixin Wang; Shijie Yang; Qingxiao Song; Yongping Zhu; Martha Salas; Hanjun Qin; Ubaydah Nasri; Karen M Haas; Arthur D Riggs; Ryotaro Nakamura; Paul J Martin; Aimin Huang; Defu Zeng
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

9.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

10.  An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Authors:  Jonathan C Poe; Wei Jia; Hsuan Su; Sarah Anand; Jeremy J Rose; Prasanthi V Tata; Amy N Suthers; Corbin D Jones; Pei Fen Kuan; Benjamin G Vincent; Jonathan S Serody; Mitchell E Horwitz; Vincent T Ho; Steven Z Pavletic; Frances T Hakim; Kouros Owzar; Dadong Zhang; Bruce R Blazar; Christian W Siebel; Nelson J Chao; Ivan Maillard; Stefanie Sarantopoulos
Journal:  Blood       Date:  2017-08-29       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.